LB Pharmaceuticals Inc Common Stock (LBRX)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 27
- Market Cap
- $1.4B
About LB Pharmaceuticals Inc Common Stock
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
SentiSense also tracks daily options readings for LB Pharmaceuticals Inc Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
LB Pharmaceuticals Inc Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.